Background: In cancer patients, drug interactions may intensify adverse events or reduce antitumour effects. We assessed the prevalence of potential drug interactions (PDIs) among ambulatory cancer patients on i.v. treatment using an advanced screening method.
introduction
The pharmacological treatment of patients with cancer is associated with multiple side-effects [1] . Although the cause of side-effects usually lies in the toxicity of the drugs themselves, drug interactions can reinforce or intensify adverse events and even seem to be the cause of death in 4% of cancer patients [2] . Cancer patients are particularly susceptible for drug interactions as they often use several drugs as part of the cancer treatment on top of the medication prescribed to manage comorbidities [3] .
Potential drug interactions (PDIs) in nature are subdivided into pharmacokinetic and pharmacodynamic interactions [4] . Pharmacokinetic interactions alter the absorption, distribution, metabolism, or excretion of a drug. The majority of pharmacokinetic interactions are the result of inhibiting or inducing the cytochrome P450 liver enzymes [3] . Since many anticancer agents are metabolised via this mechanism [5] , PDIs involving cytochrome P450 may occur. A pharmacodynamic interaction is characterised by an additive, synergistic, or antagonistic effect, thereby influencing the response of a drug [4] .
The occurrence of PDIs in general clinical practice and their determinants has extensively been studied [2, [6] [7] [8] [9] . However, only limited data are available on the occurrence of PDIs in patients being treated with anticancer agents and, to our knowledge, there is no study available that has included over-the-counter (OTC) medication. In a Canadian study in ambulatory cancer patients, it has been shown that 27% of cancer patients were exposed to PDIs involving anticancer agents [3] . Certain types of cancers (mainly brain tumours) and comorbidities appeared to be risk factors. In hospitalised cancer patients, the use of eight or more drugs and a hospital stay of >6 days were identified as risk factors for PDIs [10] . OTC medication is popular in cancer patients, either to prevent or treat symptoms of disease or to promote health and well-being [11] .
Due to the lack of information about the drugs in use to treat comorbidities, prescribing oncologists may not always be aware of PDIs in their patients. In addition, since the community pharmacy is usually not informed by the oncologist on the treatment with anticancer agents, general practitioners may not be aware of PDIs when prescribing drugs for a new complaint. OTC medication is not always identified.
Although computer-based medication prescription systems are in use in hospitals as well as in community pharmacies, they are not linked. Electronic identification of PDIs between drugs to treat comorbidities and anticancer agents is not yet available.
The aim of the present study was to gain more insight into the prevalence of PDIs among ambulatory cancer patients on i.v. treatment of an (haemato-) oncological disease using a novel more extensive screening method. The prevalence of PDIs with OTC drugs was also analysed. Possible risk factors for the occurrence of these potential drug-related problems were investigated as well.
patients and methods

study design
A two-centre cross-sectional study of the epidemiology of PDIs was carried out during a 5-month period in 2009 among all ambulatory cancer patients treated i.v. with anticancer agents at the (haemato-) oncology outpatient day care department of the VU University Medical Center and the Zaans Medical Center. The VU University Medical Center is a large tertiary referral hospital, while the Zaans Medical Center is a small community hospital situated in the Amsterdam area. The study was registered under number NTR2238.
patients
All patients with a solid tumour or a haematological malignancy on i.v. treatment with anticancer agents were asked to participate in the study. Exclusion criteria were as follows: unable to fill out questionnaires, the use of clinical trial medication, a lack of command of the Dutch language, and age <18 years. All participating patients were asked to sign an informed consent. The study was approved by the medical ethics review board of both institutes.
procedures
Patients were asked questions by means of a structured interview (RWFVL). Questions concerned comorbidities and the use of OTC drugs. To determine the type of comedication, an overview of drugs prescribed over the previous 6 months was obtained from the community pharmacy. The actual use, both on a continuous base and an incidental use, was discussed with the patient. Data on the type of anticancer agents, diagnosis, aim of treatment (palliative/adjuvant), treatment start date, and comedication in use for administration of anticancer agents were collected by means of a medical chart review and, if necessary, by means of an interview of the prescribing doctor. Data on renal function (creatinine) and liver function tests [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and c-glutamyltransferase (c-GT)] were obtained from the laboratory database of the hospital. We defined a laboratory abnormality as an increase of 50% or higher above the upper limit of normal as measured within the 4 weeks preceding the interview (upper normal limits: AST £35 U/l, ALT £40 U/l, c-GT £44 U/l, creatinine £99 lmol/l).
Drugs were subdivided into four groups: anticancer agents, supportive care drugs, drugs to treat comorbidity, and OTC drugs. We defined 'anticancer agents' as medication to treat solid tumours or haematological malignancies, 'supportive care agents' as medication to treat cancer-and/or therapy-related symptoms, 'drugs to treat co-morbidity' as a noncancer clinical condition that required pharmacological treatment, and 'OTC drugs' as (alternative) drugs and food supplements used by the patients on their own initiative without prior consultation of a doctor. For each patient, we counted the number of drugs by group. If a drug contained two or more pharmacologically active ingredients, each drug was counted individually in the analysis (e.g. sulfamethoxazole combined with trimethoprim). The drug was counted only once when a patient was taking the same medication in more than one formulation (e.g. long-and short-acting morphine).
Drugs were screened for PDIs by the Drug Interaction Facts software (Facts and Comparisons, version 4.0) [12] , which has been shown to have an accuracy of >95% in detecting interactions [13] . The Drug Interaction Facts software for PDIs classifies interactions by the level of severity and the level of scientific evidence ( Table 1 ). The potential severity of a PDI was classified as major if the effects are potentially life threatening or capable of causing permanent damage; moderate, when the effects may cause a deterioration in a patient's clinical status or if an additional treatment, hospitalisation, or an extended hospital stay may be necessary; or minor, if the effects are usually mild and should not significantly affect the therapeutic outcome. The level of scientific evidence of a PDI was classified on a five-point documentation scale. Level 1 means that a PDI was supported by well-controlled human studies and level 5 means that the documentation of a PDI is of poor quality or only theoretical. Of note, PDIs that might result in reduced anticancer activity were not scored as severe if the interaction would lead to lower toxicity, such as the combination of irinotecan and St John's wort [14] .
Drugs were also screened by a clinical pharmacologist for combinations of drugs with potential QT interval prolongation and/or torsades de pointes-inducing properties using the Arizona Center for Education and Research on Therapeutics system [15] and peer-reviewed reports on scientific evidence for potential QT interaction. Because of the potentially severe consequences, we classified all drug combinations with risk for QT interval prolongation as major. Drugs associated with an increased risk of falling [central nervous system (CNS) depressant agents] were identified manually using handbooks and peer-reviewed reports on scientific evidence. A combination of two CNS depressant agents was counted as one interaction, defined as a CNS interaction in the analysis. All CNS interactions were classified as moderate. Drugs were also screened for the combination between nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, anticoagulants, aspirin, or selective serotonin reuptake inhibitors (SSRIs) defined as gastrointestinal (GI) interaction using the Drug Interaction Facts software and peer-reviewed reports on scientific evidence. These combinations are known to increase the risk for GI bleeding. Because of the potentially severe consequences, all GI interactions were classified as major.
To identify PDIs involving OTC drugs, pharmacology handbooks and peer-reviewed reports were screened manually. Theoretical interactions were not included in the analysis. Because of lack of clinical significance, interactions of minor severity were also excluded. The medication screened for PDIs were the drugs in the four groups mentioned above: anticancer agents, supportive care drugs, drugs to treat comorbidity, and OTC drugs. A PDI was only counted in the analysis when an anticancer agent or a supportive care drug was involved.
statistical analysis
Descriptive statistics (mean 6 standard deviation or median) were applied to characterise the whole study sample with regard to demographics, cancer type, treatment objective, type of anticancer agents, comorbidities, number of drugs per patient, laboratory abnormalities, and interaction characteristics (severity, level of scientific evidence, onset, and mechanism).
Univariate and multivariate logistic regression analyses were carried out to identify the potential risk factors for the occurrence of PDIs. The number of potential interactions per patient was the dependent variable. Covariables were age, number of drugs, study centre (Zaans Medical Center and VU University Medical Center), treatment intent, treatment type, presence of comorbidities, cancer type, tumour type (haemato-oncology/oncology), laboratory abnormalities, and the use of an OTC drug. Gender was not included as a covariable due to the fact that certain cancer types only occur in men or women. For binary or nominal variables, the largest group was taken as the reference. Variables with univariate P values <0.05 were included in the multivariate analysis. In the multivariate analysis, a P value of <0.05 was considered statistically significant. The data were adjusted for confounders and effect modifiers. Tables 4 and 5 , respectively. Almost 20% of all PDIs could be attributed to a drug combination with coumarins, quinolones, antiepileptics, or hydrochlorothiazide. The other 80% of the PDIs showed a wide variety of drug classes. PDIs that may result in QT interval prolongation, GI toxicity, and CNS depression (falling) accounted for, respectively, 16%, 11%, and 33% of all PDIs.
potential risk factors
In the univariate analysis, the number of drugs, the presence of comorbidities, and the use of OTC drugs were associated with a higher number of PDIs (Table 6 ). Age was not associated with a higher number of PDIs (P = 0.223). When patients were divided into two groups comprising younger and older than 61 years, age was also without effect. Although this subgroup was small, the use of mAbs as monotherapy showed a lower risk. After adjustment for confounders, the effect of the number of drugs and the use of an OTC drug remained significant (P < 0.001 and P = 0.045, respectively).
discussion
This study showed that the occurrence of PDIs in ambulatory cancer patients was high, with more than half of the patient group presenting with at least one PDI. This situation is even more alarming because one-third of the patients had a major PDI that may result in serious clinical consequences. The majority of the major and moderate PDIs were supported by scientific evidence of level 2 or 3 (probable or suspected). We also found that 80% of the patients used OTC drugs, which resulted in 10% of cases with a PDI. This is particularly alarming because the use of OTC drugs is generally not registered either in the patient's medical chart or at the community pharmacy. Another important finding in this study was the high prevalence of PDIs that may result in serious adverse events, including QT interval prolongation, GI toxicity, and CNS depression (falling). This has not previously been described in literature and is of particular concern because of the high risk of harm to the patients' quality of life and increase of health care costs.
Numerous drugs representing a wide range of pharmacological classes have been associated with QT interval prolongation. The possibly serious and even fatal consequences of drug combinations that may cause prolongation of the QT interval have resulted in the recommendation to avoid the prescription of many drug combinations [15] . Due to the extensive use of QT interval prolongation drugs, such as quinolones, doxorubicin, and ondansetron by cancer patients, QT interactions may form a significant problem in (haemato-) oncology.
Falling in elderly patients is a major public health concern. Prescribed CNS depressant medication is an important contributor to the risk of falling in elderly people and the use of multiple CNS depressant agents may even increase this risk [41, 42] . Several commonly used drugs (e.g. psychotropic and cardiovascular drugs) are identified as a risk factor for falls [43] [44] [45] . These CNS interactions may be specifically harmful in cancer patients due to the high prevalence of osteoporosis and thereby the risk for hip fractures [46] .
NSAIDs are frequently prescribed for pain related to cancer. However, their use should be restricted because of potential GI toxicity. Additional pharmacological risk factors for the development of NSAID-related ulcers include concomitant use of corticosteroids, anticoagulants, aspirin, and SSRIs [47, 48] . Due to the extensive use of corticosteroids and anticoagulants, these PDIs are of particular concern in (haemato-) oncology.
The number of drugs and the use of one or more OTC drugs were associated with an increased risk for the occurrence of PDIs. It is to be expected that the number of drugs is a determinant, simply because the number of drug 
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combinations is increased. This finding is in agreement with other studies [3] . The association of OTC drugs with the increased number of PDIs shows that these drugs are often involved in PDIs. The strength of this study is the high response since all patients were willing to participate. In addition, the study was carried out in two hospitals. These factors increase the representativeness of the data. We also used an advanced screening method for the detection of PDIs, which led to more valuable data on the occurrence of PDIs. The inclusion of OTC drugs in the analysis resulted in findings that are unique on their own. The cross-sectional design forms another strength of the study. The patients were interviewed on the basis of their medication overview obtained from the community pharmacy and their medical chart, which increased the validity of the data on drugs taken. However, a prospective study would provide the opportunity to investigate the clinical consequences of PDIs. PDIs not involving an anticancer agent or a supportive drug were excluded in this study but may also be a subject for future analysis.
In conclusion, the present study shows a high prevalence of PDIs in ambulatory cancer patients. It is not known to what extent medical doctors were aware of these PDIs and whether they had made attempts to avoid a particular combination of drugs or took measures to prevent complications of PDIs. Buajordet et al. [2] have suggested that drug interactions are responsible for the death of 4% of hospitalised cancer patients. Therefore, oncologists might largely be unaware of interactions of anticancer agents or supportive care drugs with medication to treat comorbidities or the use of OTC drugs or they may underestimate the risk of a PDI. Professional insight into the clinical consequences of PDIs in cancer patients is not well known and should be further explored. Physicians and clinical pharmacists must collaborate to develop a routine computer-based screening method to identify PDIs upon drug prescription, which includes the awareness of the use of OTC drugs.
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